Programme (website embed only)

Psychedelics in psychiatric disorders: Where are we now and where to next?

Tracks

Track 1

Friday, November 1, 2024

10:30 AM - 11:15 AM

Plenary Room

Details

In this session panellists will deconstruct the recent FDA decision regarding the Lykos P3 clinical trial of MDMA in PTSD, the potential impact on global and Australian patients and markets in terms of drug development new treatment options and protocols, and the development of new therapeutics in the psychedelic space for patients with psychiatric disorders.

Speaker

Agenda Item Image

Ms Sharon Charles

VP Clinical Operations

ProPharma

Panellist

Agenda Item Image

Mr Roy Gustini

Commercial Growth Manager

Cortexa

Panellist

Agenda Item Image

Prof. Robyn Langham

Chief Medical Officer TGA & HREC Chair

Royal Children’s Hospital, Melbourne

Panellist

Agenda Item Image

Prof Chris Langmead

Director, Neuromedicines Discovery Centre

Monash University

Chair

Prof Suresh Sundram

Head, Dept. of Psychiatry

Monash University

Panellist

You need to enable JavaScript to access this site.

Follow these instructions on how to enable JavaScript.

Internet Explorer

Select Tools from the top menu
Choose Internet Options
Click on the Security tab
Click on Custom Level
Scroll down until you see the section labelled Scripting
Under Active Scripting, select Enable and click OK

Google Chrome

Select the menu icon on the browser toolbar
Select Settings
Click the Show advanced settings... link then Content Settings in the Privacy section
Select Allow all sites to run JavaScript (recommended) and click Done

Safari (Mac)

Select Safari from the top menu
Choose Preferences
Choose Security
Select the checkbox next to Enable JavaScript